BR112014014403A8 - "formulação de apolipoproteína, seus método de produção e uso no tratamento profilático ou terapêutico de doenças cardiovasculares, hipercolesterolemia ou hipocolesterolemia, bem como kit - Google Patents
"formulação de apolipoproteína, seus método de produção e uso no tratamento profilático ou terapêutico de doenças cardiovasculares, hipercolesterolemia ou hipocolesterolemia, bem como kitInfo
- Publication number
- BR112014014403A8 BR112014014403A8 BR112014014403A BR112014014403A BR112014014403A8 BR 112014014403 A8 BR112014014403 A8 BR 112014014403A8 BR 112014014403 A BR112014014403 A BR 112014014403A BR 112014014403 A BR112014014403 A BR 112014014403A BR 112014014403 A8 BR112014014403 A8 BR 112014014403A8
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- prophylactic
- apolipoprotein
- therapeutic treatment
- hypocholesterolemia
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 6
- 102000007592 Apolipoproteins Human genes 0.000 title abstract 5
- 108010071619 Apolipoproteins Proteins 0.000 title abstract 5
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 3
- 230000000069 prophylactic effect Effects 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 208000035150 Hypercholesterolemia Diseases 0.000 title abstract 2
- 206010020961 Hypocholesterolaemia Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 abstract 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 1
- 229940099352 cholate Drugs 0.000 abstract 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000007056 liver toxicity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- -1 sphingomyelin Chemical compound 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011905368A AU2011905368A0 (en) | 2011-12-21 | Dosing regime for apolipoprotein formulations | |
| PCT/AU2012/001345 WO2013090978A1 (en) | 2011-12-21 | 2012-11-02 | Dosage regime for apolipoprotein formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014014403A2 BR112014014403A2 (pt) | 2017-06-13 |
| BR112014014403A8 true BR112014014403A8 (pt) | 2021-03-09 |
Family
ID=48667485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014014403A BR112014014403A8 (pt) | 2011-12-21 | 2012-11-02 | "formulação de apolipoproteína, seus método de produção e uso no tratamento profilático ou terapêutico de doenças cardiovasculares, hipercolesterolemia ou hipocolesterolemia, bem como kit |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20140378376A1 (enExample) |
| EP (1) | EP2793913B1 (enExample) |
| JP (2) | JP6144276B2 (enExample) |
| KR (3) | KR102766038B1 (enExample) |
| CN (2) | CN104010646A (enExample) |
| AU (1) | AU2012310259C1 (enExample) |
| BR (1) | BR112014014403A8 (enExample) |
| CA (1) | CA2857968A1 (enExample) |
| DK (1) | DK2793913T3 (enExample) |
| ES (1) | ES2955110T3 (enExample) |
| IL (1) | IL233236A0 (enExample) |
| MX (1) | MX377093B (enExample) |
| PL (1) | PL2793913T3 (enExample) |
| RU (1) | RU2014129505A (enExample) |
| SG (1) | SG11201402556RA (enExample) |
| WO (1) | WO2013090978A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9645037B2 (en) | 2011-09-28 | 2017-05-09 | Hunter Engineering Company | Method and apparatus for wheel assembly lateral force measurement |
| KR102766038B1 (ko) * | 2011-12-21 | 2025-02-12 | 시에스엘 리미티드 | 아포지질단백질 제형을 위한 용량 용법 |
| CN116196395A (zh) | 2016-11-10 | 2023-06-02 | 杰特有限公司 | 心肌梗塞的重构的高密度脂蛋白治疗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61152632A (ja) * | 1984-12-26 | 1986-07-11 | Dai Ichi Seiyaku Co Ltd | 抗動脈硬化剤 |
| US5652339A (en) | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| AU2002213843B2 (en) * | 2000-11-10 | 2008-02-07 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
| CA2460787A1 (en) * | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
| JP2006507223A (ja) * | 2002-05-17 | 2006-03-02 | エスペリオン セラピューティクス，インコーポレイテッド | 脂質代謝異常疾患の治療方法 |
| EP1545576A2 (en) | 2002-07-30 | 2005-06-29 | Esperion Therapeutics Inc. | Methods of using non-human animal apoliprotein a-i protein |
| PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| AP2006003578A0 (en) * | 2003-10-20 | 2006-04-30 | Esperion Therapeutics Inc | Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes. |
| JP2009505652A (ja) * | 2005-08-26 | 2009-02-12 | セレニス セラピューティクス ホールディング エスア | 乳酸菌においてアポリポタンパク質遺伝子生成物を生成するための組成物および方法 |
| US20090297577A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of Apolipoproteins and Their Derivatives |
| KR102766038B1 (ko) * | 2011-12-21 | 2025-02-12 | 시에스엘 리미티드 | 아포지질단백질 제형을 위한 용량 용법 |
-
2012
- 2012-11-02 KR KR1020207009276A patent/KR102766038B1/ko active Active
- 2012-11-02 CN CN201280063210.4A patent/CN104010646A/zh active Pending
- 2012-11-02 ES ES12859136T patent/ES2955110T3/es active Active
- 2012-11-02 KR KR1020197019295A patent/KR20190084334A/ko not_active Ceased
- 2012-11-02 JP JP2014547627A patent/JP6144276B2/ja active Active
- 2012-11-02 AU AU2012310259A patent/AU2012310259C1/en active Active
- 2012-11-02 DK DK12859136.9T patent/DK2793913T3/da active
- 2012-11-02 SG SG11201402556RA patent/SG11201402556RA/en unknown
- 2012-11-02 KR KR1020147020291A patent/KR20140107536A/ko not_active Ceased
- 2012-11-02 WO PCT/AU2012/001345 patent/WO2013090978A1/en not_active Ceased
- 2012-11-02 EP EP12859136.9A patent/EP2793913B1/en active Active
- 2012-11-02 US US14/364,764 patent/US20140378376A1/en not_active Abandoned
- 2012-11-02 PL PL12859136.9T patent/PL2793913T3/pl unknown
- 2012-11-02 CA CA2857968A patent/CA2857968A1/en not_active Abandoned
- 2012-11-02 CN CN202110675512.8A patent/CN113398245A/zh active Pending
- 2012-11-02 BR BR112014014403A patent/BR112014014403A8/pt not_active Application Discontinuation
- 2012-11-02 RU RU2014129505A patent/RU2014129505A/ru unknown
- 2012-11-02 MX MX2014006589A patent/MX377093B/es active IP Right Grant
-
2014
- 2014-06-18 IL IL233236A patent/IL233236A0/en active IP Right Grant
-
2016
- 2016-02-26 US US15/054,358 patent/US20160175392A1/en not_active Abandoned
-
2017
- 2017-03-10 JP JP2017045676A patent/JP2017128586A/ja active Pending
-
2023
- 2023-08-14 US US18/449,039 patent/US20240216467A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012014928A (es) | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. | |
| NZ743714A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| BR112018007145A2 (pt) | ácidos pirazolo[3,4-b]piridin-6-carboxílicos substituídos e o seu uso | |
| BR112018007161A2 (pt) | pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso | |
| CY1123945T1 (el) | Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες | |
| CR20180086A (es) | Tricíclicos sustituidos y métodos para usarlos | |
| BR112015002584A8 (pt) | uso de lipossoma e composição farmacêutica | |
| JP2017528437A5 (enExample) | ||
| BR112015022819A2 (pt) | formulações modificadas de lipossoma de docetaxel | |
| BR112018072047A2 (pt) | moduladores da proteína reguladora de condutância transmembranar de fibrose cística | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| BRPI0408897A (pt) | derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade | |
| EP2750667A4 (en) | LIPID PRECONCENTRATE WITH DELAYED RELEASE FROM A PHARMACOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| BR112015026513A2 (pt) | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares | |
| EA201690283A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
| CY1115573T1 (el) | Τροποποιημενα ενζυμα λεκιθινοχοληστερολικης ακυλοτρανσφερασης | |
| BR112014014403A8 (pt) | "formulação de apolipoproteína, seus método de produção e uso no tratamento profilático ou terapêutico de doenças cardiovasculares, hipercolesterolemia ou hipocolesterolemia, bem como kit | |
| BR112015022415A2 (pt) | composições de cisplatina lipossômica para terapia contra câncer | |
| EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
| WO2012119781A3 (en) | Novel lipids, phospholipids, phospholipid and lipid compositions and their use | |
| JP2015535263A5 (enExample) | ||
| NZ631131A (en) | Reconstituted hdl formulation | |
| EA200801815A1 (ru) | Дибензиламиносоединения и производные | |
| BRPI0515906A (pt) | composto de 1, 2, 3, 4-tetrahidroquinolina 2 substituìdos 4-aminosubstituìdos, seus usos, bem como suas composições farmacêuticas e composições de combinações farmacêuticas | |
| JP2015500840A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: CSL LIMITED (AU) |